Hepion Pharmaceuticals, Inc. (HEPA:OTC) closed at $0.131 on October 23, 2026, up 1.04% on the day. The stock trades 15.4% below its 52-week high of $0.155 and 286.5% above its 52-week low of $0.034. Hepion Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.
Find more stocks like HEPA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.